UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549
FORM 8-K
CURRENT REPORT
Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934
| | | |
| Date of Report (Date of Earliest Event Reported): | | October 11, 2006 |
AVALON PHARMACEUTICALS, INC.
__________________________________________
(Exact name of registrant as specified in its charter)
| | | |
| Delaware | 001-32629 | 52-2209310 |
_____________________
(State or other jurisdiction | _____________
(Commission | ______________
(I.R.S. Employer |
| of incorporation) | File Number) | Identification No.) |
| | | |
| 20358 Seneca Meadows Parkway, Germantown, Maryland | | 20876 |
_________________________________
(Address of principal executive offices) | | ___________
(Zip Code) |
| | | |
| Registrant’s telephone number, including area code: | | 301-556-9900 |
Not Applicable
______________________________________________
Former name or former address, if changed since last report
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:
[ ] Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
[ ] Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
[ ] Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
[ ] Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
Item 5.02 Departure of Directors or Principal Officers; Election of Directors; Appointment of Principal Officers.
(d) Appointment of Director
On October 11, 2006, the Board of Directors of Avalon Pharmaceuticals, Inc. (the "Company") appointed a new director, David Kabakoff, Ph.D., to the Company's Board of Directors, after increasing the number of directors from nine to ten. Dr. Kabakoff's term will expire at the 2007 annual meeting of the Company's stockholders.
In addition, Dr. Kabakoff was appointed to the Nominating and Corporate Governance Committee of the Board of Directors.
There is no arrangement or understanding between Dr. Kabakoff and any other person pursuant to which he was selected as a director, and there are no transactions between Dr. Kabakoff and the Company since the beginning of the Company's last fiscal year or any currently proposed transaction, or series of similar transactions, in which the amount involved exceeds $60,000.
A copy of the press release announcing the appointment of Dr. Kabakoff as director is attached as Exhibit 99.1 to this Current Report on Form 8-K and incorporated into this Item 5.02 by reference.
Item 9.01 Financial Statements and Exhibits.
(d) Exhibits
99.1 - Press Release dated October 13, 2006.
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
| | | | | |
| | | AVALON PHARMACEUTICALS, INC. |
| | | | | |
| October 16, 2006 | | By: | | /s/ Thomas G. David, Esq.
|
| | | | |
|
| | | | | Name: Thomas G. David, Esq. |
| | | | | Title: General Counsel |
Exhibit Index
| | | |
| Exhibit No. | | Description |
| |
|
99.1 | | Press Release dated October 13, 2006 |
